{"filing":{"accession_number":"0001193125-26-403481","cik":"0001468748","ticker":"KOD","company_name":"Kodiak Sciences Inc.","form":"8-K","filing_date":"2026-09-28","report_date":"2026-09-28","primary_document":"d185059d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1468748/000119312526403481/d185059d8k.htm"},"events":[{"id":35354,"run_id":32560,"accession_number":"0001193125-26-403481","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Kodiak announced that primary endpoints were met for both Zenkuda and tabirafusp-ted in the Phase 3 DAYBREAK study in wet AMD, with Zenkuda demonstrating strong efficacy and durability (54% of patients on 6-month dosing). The company plans to submit a multi-indication BLA in Q4 2026. This is a material clinical milestone for a precommercial biotech company advancing toward regulatory approval and commercialization, but it is not a financial result (earnings_release), M\u0026A activity, or other specifically-named event type—it is a major operational/clinical development milestone.","company_name":"Kodiak Sciences Inc.","ticker":"KOD","filing_date":"2026-09-28","form":"8-K","submitted_at":null,"items":[{"id":39380,"accession_number":"0001193125-26-403481","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Kodiak announced that primary endpoints were met for both Zenkuda and tabirafusp-ted in the Phase 3 DAYBREAK study in wet AMD, with Zenkuda demonstrating strong efficacy and durability (54% of patients on 6-month dosing). The company plans to submit a multi-indication BLA in Q4 2026. This is a material clinical milestone for a precommercial biotech company advancing toward regulatory approval and commercialization, but it is not a financial result (earnings_release), M\u0026A activity, or other specifically-named event type—it is a major operational/clinical development milestone.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T12:58:08.185119+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39380,"accession_number":"0001193125-26-403481","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Kodiak announced that primary endpoints were met for both Zenkuda and tabirafusp-ted in the Phase 3 DAYBREAK study in wet AMD, with Zenkuda demonstrating strong efficacy and durability (54% of patients on 6-month dosing). The company plans to submit a multi-indication BLA in Q4 2026. This is a material clinical milestone for a precommercial biotech company advancing toward regulatory approval and commercialization, but it is not a financial result (earnings_release), M\u0026A activity, or other specifically-named event type—it is a major operational/clinical development milestone.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T12:58:08.185119+00:00","company_name":"Kodiak Sciences Inc.","ticker":"KOD","filing_date":"2026-09-28"}]}